Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Global pharmaceutical company Eli Lilly (NYSE:LLY ... beating analysts’ expectations by 3%, and Johnson & Johnson reported revenues up 5.3%, in line with consensus estimates.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Eli Lilly and Co., Amgen and Bristol Myers Squibb — due to announce results. Johnson & Johnson and AbbVie have already reported with both beating estimates for both earnings and sales.
Recent health news highlights a range of developments from Uganda discharging Ebola patients to drugmakers seeking safer ...
Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to severely active Crohn's disease receiving two years of continuous treatment ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results